156 related articles for article (PubMed ID: 17390068)
1. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.
Meynard D; Le Morvan V; Bonnet J; Robert J
Oncol Rep; 2007 May; 17(5):1213-21. PubMed ID: 17390068
[TBL] [Abstract][Full Text] [Related]
2. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
Yokoo S; Masuda S; Yonezawa A; Terada T; Katsura T; Inui K
Drug Metab Dispos; 2008 Nov; 36(11):2299-306. PubMed ID: 18710896
[TBL] [Abstract][Full Text] [Related]
3. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
[TBL] [Abstract][Full Text] [Related]
4. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
5. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
6. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
Boyer J; Allen WL; McLean EG; Wilson PM; McCulla A; Moore S; Longley DB; Caldas C; Johnston PG
Cancer Res; 2006 Mar; 66(5):2765-77. PubMed ID: 16510598
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
9. Impact of oxaliplatin and a novel DACH-platinum complex in the gene expression of HCT116 colon cancer cells.
Pang SK; Yu CW; Guan H; Au-Yeung SC; Ho YP
Oncol Rep; 2008 Nov; 20(5):1269-76. PubMed ID: 18949432
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K
Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases.
Kornmann M; Fakler H; Butzer U; Beger HG; Link KH
Anticancer Res; 2000; 20(5A):3259-64. PubMed ID: 11062751
[TBL] [Abstract][Full Text] [Related]
12. Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents.
Jung JJ; Jeung HC; Lee JO; Kim TS; Chung HC; Rha SY
Oncol Rep; 2007 Sep; 18(3):593-9. PubMed ID: 17671706
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
14. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells.
Chiu SJ; Hsu TS; Chao JI
Toxicol Lett; 2006 Dec; 167(2):122-30. PubMed ID: 17045763
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
18. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
Pendyala L; Creaven PJ
Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
[TBL] [Abstract][Full Text] [Related]
19. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance.
Samimi G; Manorek G; Castel R; Breaux JK; Cheng TC; Berry CC; Los G; Howell SB
Cancer Chemother Pharmacol; 2005 Jan; 55(1):1-11. PubMed ID: 15378272
[TBL] [Abstract][Full Text] [Related]
20. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
Duale N; Lindeman B; Komada M; Olsen AK; Andreassen A; Soderlund EJ; Brunborg G
Mol Cancer; 2007 Aug; 6():53. PubMed ID: 17711579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
